Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)’s traded shares stood at 0.5 million during the last session, with the company’s beta value hitting 2.47. At the close of trading, the stock’s price was $1.59, to imply an increase of 1.92% or $0.03 in intraday trading. The ELOX share’s 52-week high remains $6.77, putting it -325.79% down since that peak but still an impressive 25.79% since price per share fell to its 52-week low of $1.18. The company has a valuation of $138.76M, with an average of 0.3 million shares in intraday trading volume over the past 10 days and average of 697.30K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Eloxx Pharmaceuticals Inc. (ELOX), translating to a mean rating of 2.20. Of 4 analyst(s) looking at the stock, 0 analyst(s) give ELOX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.13.
Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) trade information
After registering a 1.92% upside in the last session, Eloxx Pharmaceuticals Inc. (ELOX) has traded red over the past five days. The stock hit a weekly high of 1.6600 this Friday, 10/08/21, jumping 1.92% in its intraday price action. The 5-day price performance for the stock is -1.24%, and 3.92% over 30 days. With these gigs, the year-to-date price performance is -60.05%. Short interest in Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX) saw shorts transact 1.91 million shares and set a 1.73 days time to cover.
Analysts on Wall Street suggest a consensus price target of $3.78, implying an increase of 57.94% to the stock’s current value. The extremes give us $3.00 and $5.00 for target low and target high price respectively. As such, ELOX has been trading -214.47% off suggested target high and -88.68% from its likely low.
Eloxx Pharmaceuticals Inc. (ELOX) estimates and forecasts
Looking at statistics comparing Eloxx Pharmaceuticals Inc. share performance against respective industry, we note that the company has underperformed competitors. Eloxx Pharmaceuticals Inc. (ELOX) shares are -41.11% down over the last 6 months, with its year-to-date growth rate lower than industry average at -20.93% against 7.00%. Revenue is forecast to grow 18.80% this quarter before jumping 6.70% for the next one.
Eloxx Pharmaceuticals Inc. has its next earnings report out between August 04 and August 09. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Eloxx Pharmaceuticals Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Eloxx Pharmaceuticals Inc. (NASDAQ:ELOX)’s Major holders
Eloxx Pharmaceuticals Inc. insiders hold 9.37% of total outstanding shares, with institutional holders owning 34.36% of the shares at 37.91% float percentage. In total, 34.36% institutions holds shares in the company, led by Vanguard Group, Inc. (The). As of Jun 29, 2021, the company held over 3.06 million shares (or 8.52% of shares), all amounting to roughly $6.08 million.
The next major institution holding the largest number of shares is Nantahala Capital Management, LLC with 2.27 million shares, or about 6.32% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $4.51 million.
We also have Vanguard Total Stock Market Index Fund and Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Eloxx Pharmaceuticals Inc. (ELOX) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 0.61 million shares. This is just over 1.69% of the total shares, with a market valuation of $2.02 million. Data from the same date shows that the other fund manager holds a little less at 0.37 million, or 1.02% of the shares, all valued at about 0.73 million.